Table 1.
Cancer | Peptide | Year | Author | Reference |
---|---|---|---|---|
Pancreatic cancer | uMMP-2 and uTIMP-1 | 2014 | Roy et al. | [10] |
MIC-1/GDF15 | 2014 | Wang et al. | [11] | |
RGS6 | 2014 | Jiang et al. | [12] | |
| ||||
Gastric cancer | LGR5 | 2013 | Zheng et al. | [13] |
PGI/II, CA242 | 2014 | Lu et al. | [14] | |
| ||||
Prostate cancer | EN2 | 2013 | McGrath et al. | [15] |
UCP2 | 2013 | Li et al. | [16] | |
| ||||
Breast cancer | HER-2 | 2014 | Boku | [17] |
MUC1 | 2011 | Zanetti et al. | [18] | |
| ||||
Colorectal cancer | HNP1-3 | 2006 | Albrethsen et al. | [19] |
CPAA-783-EPPT1 | 2012 | Bloch et al. | [20] | |
Serum C-peptide | 2014 | Comstock et al. | [21] | |
| ||||
Lung cancer | Linear peptide antigen derived from ANXA1 | 2014 | Wang et al. | [22] |
C-peptide in serum | 2014 | Zhang et al. | [23] | |
11 novel peptides | 2014 | McGuire et al. | [24] | |
Peptides from variable parts of antibodies | 2014 | de Costa et al. | [25] | |
HCBP-1 | 2014 | Wang et al. | [26] |